



WI
CA872
V.45
NO. 2



Cancer Research

VOLUME 45 • NO. 2 CNREA 8 • PP 481-933

February 1985



Notice to Members of the American Association for Cancer Research

Officers for 1984-1985

President: Isaiah J. Fidler, M. D. Anderson Hospital and Tumor Institute, Texas Medical Center, P. O. Box HMB-173, Houston, Texas 77030
Vice President: Arthur B. Pardee, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Mass. 02115.
Secretary-Treasurer: Robert E. Handschumacher, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510
Executive Director: Margaret Foti, Temple University School of Medicine, West Building, Room 301, Philadelphia, Pa. 19140

Annual Dues

The annual dues of active members of the American Association for Cancer Research are \$75.00 and they include a subscription to the journal *Cancer Research*. The regular subscription price of *Cancer Research* for members of the Association is \$50.00 per annual volume. Corresponding members of the Association should add \$30.00 to this rate to offset postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to the office of the American Association for Cancer Research, c/o Margaret Foti, Executive Director, American Association for Cancer Research, Temple University School of Medicine, West Building, Room 301, Philadelphia, Pa. 19140 (215-221-4565).

Back Issues and Single Copy Sales of the Journal

Copies of back stock of the journal *Cancer Research* may be ordered from Waverly Press, Inc. As long as supplies permit, single copies of *Cancer Research* will be sold by this company at \$20.00 per copy for regular issues and \$20.00 per copy for Supplement issues which contain material from conferences on topics related to cancer. The annual *Proceedings of the American Association for Cancer Research* is available at \$20.00 per copy.

Advertisements in Cancer Research

Advertisement insertion orders and copy must be received 60 days prior to the month of issue in which the advertisement is to be published. The journal is mailed on or about the 20th of the month preceding the month of issue. Inquiries about advertising should be directed to: Donald H. Nichols, Vice President, Journal Sales, Waverly Press, Inc., 428 E. Preston Street, Baltimore, Maryland 21202. Telephone: 301/528-4280.

Historical Cover Themes

Readers are invited to submit themes (events, persons, institutions) for consideration for the illustrated covers of *Cancer Research*. Correspondence regarding suggested cover themes, or other matters regarding covers, should be addressed to the Cover Editor, *Cancer Research* Editorial Office.

Submission of Manuscripts

Papers submitted for publication in *Cancer Research* and all other communications for the attention of the Editor should be sent to: Dr. Peter N. Magee, Editor, *Cancer Research*, Fels Research Institute, Temple University School of Medicine, Philadelphia, Pennsylvania 19140. Telephone: 215/221-4720. *Cancer Research* publishes original studies in all the subfields of cancer research, including: biochemistry and physiology; chemical and physical carcinogenesis and mutagenesis; clinical investigations; endocrinology; epidemiology and biostatistics; immunology; molecular and cell biology; preclinical pharmacology and experimental therapeutics; radiobiology; and virology. Clinical investigations and epidemiological studies are published in a separate section from papers in the basic sciences. Authors should consult the detailed "Instructions for Authors" printed in the January issue of the journal, copies of which are available upon request.

Manuscript Processing Fee

Journal policy requires that a manuscript processing fee of \$75.00 be assessed for each paper to defray the expenses incurred in the editorial review process. An invoice is sent to the author upon receipt of the manuscript. Review to determine acceptability will not be delayed pending payment of this fee.

Copyright and Copyright Clearance Center

The Copyright Revision Act (PL 94-553), which became effective January 1, 1978, states that the copyright of a work is vested in the author from the moment of creation. Therefore, all authors who wish to publish in *Cancer Research* must formally transfer copyright to the proprietor of the journal, Cancer Research, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, sale, and display.

Authors who prepared their articles as part of their official duties as employees of the U. S. Federal Government are not required to transfer copyright to Cancer Research, Inc., since these articles are considered to be in the public domain. However, it is necessary for these authors to sign the appropriate section of the transfer form. In the case of articles supported by federal grants or contracts, copyright transfer to Cancer Research, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.

The duly authorized agent of a commercial firm or commissioning organization must sign the transfer form if the author prepared the article as part of his or her official duties as an employee.

Appropriate forms for transfer of copyright will be sent routinely with acknowledgment of receipt of manuscripts for review. They may also be requested from the *Cancer Research* Editorial Office. The journal will not publish a paper unless the form is properly completed and signed.

Copies of articles for which *Cancer Research* owns the copyright may be made for personal or internal use, provided that the copier pay the per-copy fee of \$2.00 through the Copyright Clearance Center, Inc. This Center is a nonprofit organization through which individuals and institutions may reimburse a copyright owner for photocopying journal articles beyond what is defined as "fair use" in Sections 107 and 108 of the Copyright Revision Act of 1978.

Those who wish to photocopy *Cancer Research* articles may report the number of copies they have made, together with the fee code 0008-5472/85 \$02.00, to: Copyright Clearance Center, Inc., 21 Congress St., Salem, Mass. 01970. Remittances may be sent to the Center at the time of reporting or the Center will bill the user on a monthly basis. Deposit accounts and prepayment plans may also be arranged.

Between June 1978 and August 1983, a fee code appeared on the first page of all articles for which *Cancer Research* owned the copyright. For those issues, it is understood that any articles which did not carry this code are in the public domain.

Cancer Research is abstracted or indexed in *Biological Abstracts*, *Chemical Abstracts*, *Index Medicus*, *Science Citation Index*, and by the *International Cancer Research Data Bank*.

No responsibility is accepted by the Editors, by Cancer Research, Inc., by the American Association for Cancer Research, Inc., or by Waverly Press, Inc. for the opinions expressed by contributors or for the content of the advertisements.

Cancer Research (ISSN 0008-5472) is published monthly for \$50 per year (for members of the American Association for Cancer Research) or \$100 and \$175 per year (for nonmembers) by Cancer Research, Inc. Second-class postage paid at Baltimore, Md. and additional mailing offices. POSTMASTER: Send address changes to *Cancer Research*, c/o Waverly Press, Inc., 428 E. Preston Street, Baltimore, Md. 21202.

Copyright 1985 by Cancer Research, Inc.

Human Anti-Murine Immunoglobulin Responses in Patients Receiving Monoclonal Antibody Therapy¹

Robert W. Schroff,² Kenneth A. Foon, Shannon M. Beatty, Robert K. Oldham, and Alton C. Morgan, Jr.

Biological Therapeutics Branch, Biological Response Modifiers Program, National Cancer Institute, Frederick, Maryland 21701

ABSTRACT

Human anti-murine immunoglobulin responses were assessed in serum from three groups of patients receiving murine monoclonal antibody therapy. Each of the three patient groups responded differently. Chronic lymphocytic leukemia patients demonstrated little or no preexisting murine immunoglobulin G-reactive antiglobulin prior to treatment, while the cutaneous T-cell lymphoma and melanoma patients demonstrated preexisting antiglobulin levels in the same range as those demonstrated in healthy controls. None of 11 chronic lymphocytic leukemia patients receiving the T101 monoclonal antibody demonstrated an antiglobulin response, whereas all four of the cutaneous T-cell lymphoma patients receiving the same antibody developed increased levels of antiglobulins. Three of nine malignant melanoma patients receiving the 9.2.27 monoclonal antibody showed an increase in antiglobulin titers. In patients developing antiglobulin responses, the response was rapid, typically being detectable within 2 weeks. The antiglobulins were primarily immunoglobulin G and, with the exception of a single melanoma patient in whom the response appeared to have a substantial 9.2.27-specific component (*i.e.*, antiidiotypic), were cross-reactive with most murine immunoglobulin G preparations tested. This pattern of results suggested that the antiglobulin was a secondary immune reaction with elevation of the levels of preexisting antiglobulin which was cross-reactive with the mouse antibody administered. While the presence of serum antiglobulin would be expected to present major complications to monoclonal antibody therapy, no clinical toxicity related to antiglobulin responses was observed in these patients, and no inhibition of antibody localization on tumor cells was seen.

INTRODUCTION

Attempts at serotherapy of human tumors date back to the treatment of chronic myelogenous leukemia with antisera by Lindstrom (6) in 1927. However, due to the difficulty in obtaining large quantities of antisera of sufficient specificity, and the many side effects of crude antisera, this form of therapy has not come into general use. The development of monoclonal antibodies of defined specificity and unlimited availability has rekindled interest in the use of passively administered antibody as a form of cancer therapy (13).

The development of host antibodies against passively administered immunoglobulin, with possible neutralization of the administered immunoglobulin and anaphylactic or other immune

reactions, has been viewed as a potential major complication to serotherapy. Recent reports of clinical trials with murine monoclonal antibodies have confirmed that human anti-mouse immunoglobulin antibodies may be induced (1, 2, 10, 14, 17). Miller *et al.* (10) reported development of anti-mouse immunoglobulin antibodies in 4 of 7 T-cell lymphoma patients treated with the anti-Leu-1 monoclonal antibody. In 3 of these 4 patients, the development of anti-mouse immunoglobulin antibodies appeared to contribute to tumor escape from therapy. Similarly, Dillman *et al.* (1) attributed the lack of response to therapy, in 2 of 4 cutaneous T-cell lymphoma patients receiving the T101 monoclonal antibody, to the presence of human anti-mouse immunoglobulin antibodies. Sears *et al.* (17) also reported the presence of human anti-mouse immunoglobulin antibodies in 9 of 18 gastrointestinal tumor patients receiving the monoclonal antibody 1083-17-1A. However, other studies did not report that human antiglobulin responses presented major problems in monoclonal antibody therapy (3, 7-9, 15). The relatively small number of reports in the literature of monoclonal antibody clinical trials, the variety of diseases treated, and the lack of uniformity in the design of these trials makes it difficult to draw general conclusions as to the conditions under which host anti-mouse immunoglobulin responses would be expected to develop.

The Biological Therapeutics Branch of the National Cancer Institute has recently completed Phase I clinical trials with the IgG2a monoclonal antibody T101 in patients with CLL³ and CTCL and the IgG2a monoclonal antibody 9.2.27 in patients with malignant melanoma (2, 3, 14). The T101 antibody recognizes the T65 antigen present on the cell surface of both normal and malignant T-cells, as well as some B-cell cancers, including CLL (16). The 9.2.27 antibody recognizes a *M_r* 250,000 glycoprotein-proteoglycan associated with melanoma (11). In this paper, the host anti-mouse immunoglobulin responses observed during these trials are summarized, with a comparison of the differences and similarities in the responses elicited within the 3 disease groups, and an analysis of the specificity of the detected antibodies.

MATERIALS AND METHODS

Patients. Patients considered for the clinical trial with T101 were adults with histologically confirmed diagnosis of CLL or CTCL. Patients with malignant melanoma were considered as candidates for treatment with the 9.2.27 antibody. Patients received no radiation or immunosuppressive drugs for at least 4 weeks prior to entry into these trials. Prior to treatment, all patients were fully ambulatory and had no serious unrelated disease, and their tumor cells were positive for reactivity with the antibody to be used in therapy. The mean and range of age of each patient population was: CLL, 59, 43 to 81; CTCL, 56, 42 to 68; melanoma, 48, 23 to 72 years.

³ The abbreviations used are: CLL, chronic lymphocytic leukemia; CTCL, cutaneous T-cell lymphoma; ELISA, enzyme-linked immunosorbent assay.

¹ This project has been funded at least in part with Federal funds from the Department of Health and Human Services, under Contract N01-CO-23910 with Program Resources, Inc.

² To whom requests for reprints should be addressed, at BRMP, NCI-FCRF, Bldg. 560, Room 31-93, Frederick, MD 21701.

Received February 17, 1984; accepted November 2, 1984.

HUMAN ANTI-MURINE IMMUNOGLOBULIN RESPONSES

The control population used in this study consisted of 11 healthy individuals with no history of cancers and no previous therapy with murine-derived agents and ranged in age from 20 to 45 years, with a mean of 31 years.

Study Plan. Patients were treated with either T101 or 9.2.27 monoclonal antibody. Details of the design and clinical findings of each trial have been reported elsewhere (3, 14). Briefly, patients with CLL or CTCL received T101 antibody i.v. at fixed-dose levels of 1, 10, 50, or 100 mg. Patients were treated twice weekly for 4 weeks. Initially, patients received the total dose of antibody in 100 ml of 0.9% NaCl solution (saline) with 5% human albumin over 2 hr. Due to pulmonary toxicity associated with the rapid rate of infusion, this was later amended so that antibody was administered at a rate of no more than 1 to 2 mg of T101 antibody per hr. Melanoma patients received the 9.2.27 antibody by i.v. infusion in 100 ml of saline with 5% human serum albumin over 2 hr. Each patient received single doses of antibody twice weekly on an escalating dose schedule of 1, 10, 50, 100, and 200 mg or 10, 50, 100, 200, and 500 mg. A summary of the number of patients treated and the amount of antibody administered is presented in Table 1.

Assay for Human Anti-Mouse Antibody. Sera used in all assays were separated from peripheral blood and stored at -20° until use. Antiglobulins in dilutions of serum were measured using solid-phase T101 or 9.2.27 antibodies dried at 37° overnight onto polyvinyl plates at 100 ng of antibody per well and washed with 0.1 M tris (pH 8.3)-0.02% NaN_3 -0.5% Tween 20 (Sigma Chemical Co., St. Louis, MO). Dilutions of serum were incubated on the plates at room temperature for 45 min. Bound human immunoglobulin was detected with heavy chain-specific (γ or μ) goat anti-human immunoglobulin conjugated with alkaline phosphatase (Sigma) during a 45-min incubation. For comparison, standard curves were generated against solid-phase human IgM myeloma proteins or pooled normal human IgG (Cappel Laboratories, Cochranville, PA), and antiglobulin expressed as μg of protein bound to plates per ml of serum.

For assays of antiglobulin specificity, plates were coated with T101 Fab or 9.2.27 $\text{F}(\text{ab}')_2$ preparations (100 ng/well); the mouse myeloma proteins MOPC-21 (IgG1), RPC-5 (IgG2a), UPC-10 (IgG2a), MOPC-141 (IgG2b), and FLOPC-21 (IgG3) (Litton Bionetics, Kensington, MD); mouse IgG (Sigma); mouse IgM (Pel Freeze Biologicals, Rogers, AR); rabbit IgG (Dako, Denmark); or whole T101 or 9.2.27 antibodies. Inhibition of binding to T101 or 9.2.27 target antigen was assessed by performing the ELISA in the presence of a 1000-fold-greater concentration (100 μg /well) of the soluble inhibitor murine IgG2a antibodies 9.2.27, T101, D3, or RPC-5 as compared to the solid-phase target immunoglobulin.

Assay for Mouse Immunoglobulin. Murine immunoglobulin in dilutions of serum was assayed using affinity-purified goat anti-mouse immunoglobulin (KPL, Gaithersburg, MD) adsorbed onto polyvinyl plates at 100 ng/well and washed as above. Bound mouse immunoglobulin

was detected with a goat anti-mouse immunoglobulin conjugated with alkaline phosphatase (Sigma) and compared against a standard curve of either T101 or 9.2.27 antibody.

Assay for Human Serum Immunoglobulin. Serum IgG and IgM levels were determined by radial immunodiffusion utilizing Endoplate immunoglobulin test kits obtained from Kallestad Laboratories, Austin, TX.

Immunofluorescent Staining of Melanoma Specimens. Tumor cells were prepared as single-cell suspensions by teasing tissues which were obtained from skin lesions. To assess *in vivo* localization of the murine 9.2.27 antibody, the cell suspensions were incubated with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Tago, Inc., Burlingame, CA) for 30 min at 4° . The cells were then washed by centrifugation and analyzed on a Cytofluorograf 50H (Ortho Diagnostic Systems, Westwood, MA). A similar goat antibody directed against mouse IgM (Tago) was used as a negative control, and incubation in the presence of excess 9.2.27 antibody served as a positive control. All biopsy specimens were obtained 24 hr following infusion of the 9.2.27 antibody.

Statistical Evaluation. Serum antiglobulin levels for a given patient were considered significantly increased at antiglobulin levels greater than 2 S.D.s above the mean of the healthy control group.

RESULTS

Development of Antiglobulin Responses. In order to determine the level of mouse-reactive antiglobulins which could be detected in healthy individuals by our ELISA, antiglobulin levels were assessed in 11 normal donors. As illustrated in Chart 1, the control population demonstrated detectable levels of IgG and IgM antiglobulin reactive with both the T101 and 9.2.27 antibodies. These preexisting antiglobulin levels in the CLL patients prior to therapy were significantly lower ($p < 0.005$ by Student's *t* test) than those demonstrated by the healthy controls. Serum immunoglobulin levels were determined on the same specimens. Both serum IgG and IgM levels were significantly lower in the CLL group as compared to the control group. However, CLL serum immunoglobulin levels were roughly one half that of controls, while CLL antiglobulin levels were less than one tenth that of control antiglobulin levels.

To substantiate that the assay used was in fact detecting human anti-mouse immunoglobulin antibody, 2 control experiments were performed. To demonstrate that the binding of human immunoglobulin to the ELISA plate was not nonspecific, control and patient specimens were incubated on plates coated with either the T101 or 9.2.27 antibodies, or left uncoated. Table 2 demonstrates that binding did not occur in the absence of mouse immunoglobulin on the plates and that binding was roughly equivalent irrespective of the antibody used to coat the plates. To further substantiate that the preexisting human antibody activity was indeed reactive with mouse immunoglobulin, we performed the ELISA for human anti-mouse immunoglobulin activity in the presence of a 1000-fold-greater concentration of a variety of murine IgG2a preparations. As indicated in Table 3, roughly 50% of the activity could be inhibited in such a manner. The percentage of inhibition represents the decrease in titer due to the presence of the inhibitor immunoglobulin. While there was substantial variability between titers of antiglobulin in the 5 individuals examined, the percentage of inhibition in each case was quite similar, as indicated by the relatively low S.D. The inhibition was not restricted to the mouse immunoglobulin preparation used as the solid-phase antigen. The remaining 50% of the activity is most likely attributable to the weak affinity of antiglobulins for soluble immunoglobulin (12) as compared to the

Table 1
Summary of monoclonal antibody therapy

| No. of patients treated | Disease | Total dose received (mg) |
|-------------------------|----------|--------------------------|
| 1 | CLL | 6 |
| 2 | CLL | 8 |
| 1 | CLL | 50 |
| 2 | CLL | 80 |
| 1 | CLL | 150 |
| 1 | CLL | 300 |
| 2 | CLL | 400 |
| 1 | CTCL | 8 |
| 1 | CTCL | 66 |
| 1 | CTCL | 80 |
| 1 | CTCL | 162 |
| 7 | Melanoma | 361 |
| 2 | Melanoma | 860 |

HUMAN ANTI-MURINE IMMUNOGLOBULIN RESPONSES




Chart 1. Antiglobulin and serum immunoglobulin levels in healthy controls and patients prior to therapy. Serum IgG (A) or IgM (B) antibody levels to both T101 and 9.2.27 antibodies in controls and the appropriate treatment antibody in patients [T101 for CLL and CTCL patients, 9.2.27 for melanoma (Mel) patients] are shown (□). Serum immunoglobulin levels are indicated for comparison (■). Columns, mean of each group; bars, S.D. The number of individuals in each group was: control, 11; CLL, 11; CTCL, 4; melanoma, 9. *, levels in patient groups which were significantly lower than those of the appropriate control group ($p < 0.005$ as determined by the Student *t* test).

Table 2
Specific binding of human serum immunoglobulin in solid-phase ELISA IgG antiglobulin assay

| Serum specimen | Solid-phase target antigen | Serum dilution | | | |
|---|----------------------------|-------------------|------|-------|--------|
| | | 1:10 | 1:50 | 1:250 | 1:1250 |
| Melanoma Patient K. G. prior to 9.2.27 treatment | None ^a | 0.07 ^b | 0.00 | 0.00 | 0.00 |
| | T101 | 0.55 | 0.33 | 0.26 | 0.14 |
| | 9.2.27 | 0.47 | 0.31 | 0.24 | 0.11 |
| Melanoma Patient K. G. following 9.2.27 treatment | None | 0.04 | 0.00 | 0.00 | 0.00 |
| | T101 | 0.56 | 0.43 | 0.42 | 0.19 |
| | 9.2.27 | 0.53 | 0.49 | 0.41 | 0.20 |
| Normal control | None | 0.08 | 0.00 | 0.00 | 0.00 |
| | T101 | 0.64 | 0.35 | 0.30 | 0.10 |
| | 9.2.27 | 0.70 | 0.37 | 0.25 | 0.09 |

^a No target antigen or control protein bound to plates.

^b Mean of duplicate absorbance determinations at 405 nm.

solid-phase immunoglobulin, or to nonspecific interactions (4) such as Fc-Fc interactions between the human immunoglobulin and solid-phase murine immunoglobulin.

Antiglobulin levels were assessed in patients over the period of treatment with either T101 or 9.2.27 antibodies as the target

Table 3
Inhibition of 9.2.27-reactive human antiglobulin activity in normal human serum with murine IgG2a

Values represent the mean of 5 healthy control specimens.

| Monoclonal antibodies | Inhibitor | |
|-----------------------|----------------------|-----------------|
| | Titer ^a | % of inhibition |
| None | 70 ± 45 ^b | |
| 9.2.27 | 42 ± 30 | 42 ± 5 |
| T101 | 43 ± 36 | 41 ± 9 |
| D3 | 34 ± 27 | 51 ± 10 |
| RPC-5 | 35 ± 36 | 57 ± 17 |

^a Reciprocal of the dilution yielding an absorbance at 405 nm of 0.3.

^b Mean ± S.D.

antigens. In the T101 trial, serum specimens were obtained before the third, fifth, and seventh doses. These specimens were obtained immediately prior to doses in order to minimize the possibility of circulating free mouse IgG being present in the specimen. To confirm that serum mouse IgG levels were low, mouse IgG levels were quantitated in all serum samples. Specimens from CLL and CTCL patients all demonstrated mouse IgG levels of less than 1 µg/ml. Specimens from melanoma patients demonstrated somewhat higher levels of mouse IgG but, in all cases, were less than 25 µg/ml. As depicted in Chart 2, CLL patients treated with T101 failed to develop detectable antiglobulin levels over the period of therapy. In contrast, while CTCL patients demonstrated rather low antiglobulin levels prior to receiving T101 antibody, a significant increase in IgG levels of antiglobulin developed over the course of therapy in all 4 patients (Chart 3). Three of these 4 patients also demonstrated rises in IgM antiglobulin levels over the course of therapy, but not to the same magnitude as IgG responses.

Of the 9 melanoma patients in the 9.2.27 trial, 3 developed significant levels of IgG antiglobulin (Chart 4). These same 3 patients demonstrated lower, but yet significant, levels of IgM antiglobulin during the course of therapy. All 3 individuals who developed antiglobulin levels received a total of 361 mg of 9.2.27 antibody.

Specificity of Antiglobulin Response. In order to determine the specificity of the antiglobulin responses elicited, sera from patients who demonstrated significant elevations in antiglobulin levels were tested against a variety of immunoglobulins (Table 4). Specimens from the 4 CTCL patients were assessed for reactivity against whole T101 and a Fab fragment of T101, as well as 5 IgG murine myeloma proteins, the IgG and IgM components of normal mouse serum, and a rabbit IgG preparation. Specimens from the 3 melanoma patients who demonstrated antiglobulin responses were tested against a similar panel, with the exception that the F(ab')₂ fragment of 9.2.27 was substituted for the Fab fragment of T101.

Sera from all 4 CTCL patients and the 3 melanoma patients demonstrated substantial reactivity with whole T101 or 9.2.27, most murine myeloma proteins of the different IgG subclasses, and mouse IgG (Table 4). Little or no reactivity was observed against the Fab or F(ab')₂ fragments or to mouse IgM. These results suggest that the antiglobulin response elicited in these patients was directed to determinants common to murine IgG and was not specific for either the T101 or 9.2.27 antibody. Further, the lack of reactivity to Fab or F(ab')₂ fragments suggests that the reactivity is directed against determinants on the Fc region of the immunoglobulin molecule and not determinants,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.